Tonapofylline

DB12569InvestigationalSmall molecule

Tonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.

Mechanism: Stimulation of A1 adenosine receptors in the kidney reduces glomerular filtration rate (GFR) via tubuloglomerular feedback and increases sodium reabsorption. Blocking A1 adenosine receptors would therefore maintain GFR and cause natriuresis. Tonapofylline is a xanthine derivative that binds with high affinity to A1 adenosine receptors from several species including human and acts as a competitive antagonist at these receptors.
Curator reviewed
Formula / weight: C₂₂H₃₂N₄O₄ · 416.522 g/mol (avg)
Code names: BG-9928

Resolves to

Compound

Structure

InChIKeyZWTVVWUOTJRXKM-UHFFFAOYSA-NSMILESCCCN1C2=C(NC(=N2)C23CCC(CCC(O)=O)(CC2)CC3)C(=O)N(CCC)C1=O

Targets

What you can answer from here — as of January 29, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

17+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tonapofylline, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.